SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”) , a biotechnology company developing next-generation cell and gene therapies using ...
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene ...
And then there were two. Senti Bio, seeing the end of its cash runway hove into view, has pulled the plug on its liver cancer candidate and narrowed its focus onto two CAR-NK programs to preserve its ...
Senti Biosciences, Inc. (NASDAQ:SNTI) stock is skyrocketing on Monday, with a strong session volume of 73.4 million compared to an average volume of 17.81 thousand, as per data from Benzinga Pro. The ...
Senti Biosciences, Inc. (Nasdaq: SNTI) ('Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today ...
Senti Bio released a KOL segment discussing leukemia research and its lead program, SENTI-202, featuring Drs. Strickland and Rajangam. Senti Biosciences, Inc. has released a Virtual Investor KOL ...
Senti Biosciences (NASDAQ:SNTI) soared 29% on Tuesday after unveiling encouraging clinical data from its SENTI-202 cancer therapy program and securing Regenerative Medicine Advanced Therapy (RMAT) ...
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and ...
Curt Herberts is signing on at synthetic biology startup Senti Biosciences as its new chief financial officer and chief business officer. First up on the docket? Figuring out the company's partnering ...
Senti Biosciences, Inc. has announced that its CEO, Timothy Lu, participated in Nasdaq's Amplify Spotlight Series, where he discussed the company's proprietary Gene Circuit platform aimed at ...
Senti Biosciences, Inc. (Nasdaq: SNTI) ('Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results